scispace - formally typeset
J

Julien Vergniol

Publications -  3
Citations -  574

Julien Vergniol is an academic researcher. The author has contributed to research in topics: Sorafenib & Tare weight. The author has an hindex of 2, co-authored 3 publications receiving 407 citations.

Papers
More filters
Journal ArticleDOI

Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial

Valérie Vilgrain, +111 more
- 01 Dec 2017 - 
TL;DR: SarAH was a multicentre, open-label, randomised, controlled, investigator-initiated, phase 3 trial done at 25 centres specialising in liver diseases in France to compare the efficacy and safety of sorafenib to that of selective internal radiotherapy in patients with hepatocellular carcinoma.
Journal ArticleDOI

Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials.

Thomas Aparicio, +308 more
TL;DR: Overweight patients had a prolonged OS compared with normal weight patients with mCRC, and the association of overweight with better OS was only observed in men.
Journal ArticleDOI

Cost-Utility Analysis of Transarterial Radioembolization With Yttrium-90 Resin Microspheres Compared With Sorafenib in Locally Advanced and Inoperable Hepatocellular Carcinoma.

Kevin Zarca, +106 more
TL;DR: In this article, the authors performed a cost-utility analysis of transarterial radioembolization (TARE) versus oral sorafenib for hepatocellular carcinoma.